Lexington, MA, United States
Lexington, MA, United States

Agenus is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the power of the immune system to control or cure cancer. The company is developing checkpoint modulators , patient-specific anti-cancer vaccines, and adjuvants that can be used with a range of vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients. In light of the advances made, Science magazine hailed cancer immunotherapy as its 2013 Breakthrough of the Year. Wikipedia.


Time filter

Source Type

Patent
Agenus, Ludwig Institute for Cancer Research and Sloan Kettering Cancer Center | Date: 2016-09-01

The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.


Patent
Agenus, Sloan Kettering Cancer Center and Ludwig Institute for Cancer Research | Date: 2017-04-05

The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.


Patent
Agenus, Ludwig Institute for Cancer Research and Sloan Kettering Cancer Center | Date: 2016-05-27

The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.


Patent
Agenus, Ludwig Institute for Cancer Research and Sloan Kettering Cancer Center | Date: 2016-05-06

The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.


Patent
Agenus | Date: 2016-05-13

Provided are compositions useful as therapeutic vaccines (e.g., cancer vaccines), and methods of producing such compositions. The compositions disclosed herein generally employ a stress protein and at least one synthetic peptide, which may be a phosphopeptide or phosphopeptide mimetic, comprising a cancer-specific mutation present in a patients cancer.


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 300.00K | Year: 2016

Project summary Therapeutic strategies that seek to stimulate adaptive immunity for the treatment of cancer have recently shown convincing clinical efficacy Immune checkpoint inhibitors CPIs for example reactivate a patient s own T cells to eliminate tumors by blocking interactions that cause tumor infiltrating lymphocytes TILs to become exhausted CPIs have demonstrated remarkable success against metastatic melanoma and non small cell lung cancer and are in testing for the treatment of numerous other tumor types either alone or in combination Infiltration of the tumor by CD cytotoxic T cells appears to be a requisite for CPI treatment to be effective Accordingly CD has been identified as a potential predictive biomarker for response to CPI therapy at least in melanoma The current standard for assessment of this biomarker entails biopsy of primary and metastatic tumor foci followed by immunohistochemical characterization Limitations of biopsy include its invasiveness the difficulty of accessing tumors at many anatomical locations and sampling bias related to the heterogeneous distribution of markers both within and between tumor foci increasing the likelihood of false negative results There is an urgent need for non invasive imaging techniques that allow visualization of biomarker distribution on the entire surface of primary and metastatic tumor foci at diverse anatomical locations Bio is uniquely positioned to develop such a non invasive imaging approach Our platform exploits the advantages of single domain antibodies sdAbs combined with site specific conjugation for controlled and reproducible installation of a radio isotopic label for positron emission tomography PET imaging Due to their small size the resulting imaging agents show high tissue uptake and rapid blood clearance This design allows high PET tumor to background ratios even at low levels of antigen abundance and within to hours of injection enabling same day imaging at high resolution Mouse proof of concept experiments using radiolabelled sdAbs against specific immune markers have were successful at visualizing immune cells within lymphoid structure and tumors by PET imaging Bio has assembled a highly qualified scientific team with broad experience in protein engineering antibody discovery and development tumor immunology and nuclear medicine To complement internal capabilities we have gained access to outside facilities and have recruited a panel of expert tumor immunology and PET imaging consultants We have generated a series of mouse and human CD reactive sdAbs and propose here to a further characterize their ability to detect tumor infiltrating CD T cells in mouse models and b select and characterize the lead candidate for development toward use in humans This anti CD imaging agent offers the potential to be the first non invasive imaging agent to be used in selection and management of patients underdoing CPI cancer immunotherapy Project narrative Non invasive imaging technologies that measure biomarkers predictive of response to cancer immunotherapy are urgently needed to guide selection and management of patients undergoing treatment for diverse tumors We have generated and are characterizing high affinity single domain antibodies to the CD antigen site specifically modified with radioisotopes which will enable rapid visualization of tumor infiltrating lymphocytes with exceptional resolution and image quality We propose here to select our best performing CD antibody as a lead candidate for use in humans thereby allowing its advancement into pre clinical development


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 300.00K | Year: 2016

DESCRIPTION provided by applicant Several strategies have recently shown convincing clinical efficacy by stimulating adaptive immunity for the treatment of cancer Immune checkpoint inhibitors CpIs for example reactivate a patientandapos s own T cells to eliminate tumors by blocking interactions that cause tumor infiltrating lymphocytes TILs to become exhausted CpIs have shown significant efficacy in metastatic melanoma and are in testing for the treatment of numerous other tumor types either alone or in combination Expression of the cell surface marker PD L either on TILS at the tumor margin or on the tumor itself appears to be correlated with clinical efficacy in CpI therapy identifying it as a potential biomarker for patiet stratification and management The current standard for assessment of this biomarker entails biopsy of primary and metastatic tumor foci followed by immunohistochemical characterization Limitations of biopsy include low patient and physician acceptance due to its invasiveness and the difficulty of accessing tumors at many anatomical locations and sampling bias related to the heterogeneous distribution of markers both within and between tumor foci increasing the likelihood of false negative results There is an urgent need for non invasive imaging techniques that allow visualization of biomarker distribution on the entire surface of primary and metastatic tumor foci at diverse anatomical locations Bio is uniquely positioned to develop such a non invasive imaging approach We are developing a positron emission tomography PET agent that can non invasively image PD L Our product uses site specific conjugation for controlled and reproducible installation of a radio isotopic label on single domain antibodies sdAbs Due to its small size the resulting imaging agents show high tissue uptake and rapid renal clearance This design allows an exceptionally high PET signal to noise ratio even at low levels of antigen abundance and within hours of injection enabling same day imaging at high resolution Our mouse proof of concept experiments using radiolabelled sdAbs to specific immune cell and tumor markers shows exceptionally high resolution imaging of lymph nodes and tumors Bio has assembled a highly qualified scientific team with broad experience in protein engineering antibody discovery and development tumor immunology and nuclear medicine To supplement internal capabilities we have gained access to additional outside facilities and have recruited a panel of expert tumor immunology and PET imaging consultants We propose here to prepare PD L reactive sdAbs radiolabeled with either Zr or F The resulting imaging data will guide our selection of the optimal radiolabel for development of our radiodiagnostic product We will also formally demonstrate that human tumors can be visualized using our lead candidate antibody against PD L Finally we will humanize the sdAb in order to reduce potential immunogenicity This anti PD L imaging agent offers the potential to be the first non invasive imaging agent to be used in selection and management of patients undergoing cancer immunotherapy PUBLIC HEALTH RELEVANCE Non invasive imaging technologies that measure biomarkers predictive of response to cancer immunotherapy are urgently needed to guide selection and management of patients undergoing treatment for diverse tumors We have developed a high affinity single domain antibody to PD L site specifically modified with radioisotopes that enables rapid visualization of mouse melanoma tumors with exceptional resolution and image quality We propose here to develop an imaging agent for use in humans thereby allowing its advancement into pre clinical development


The present invention relates to methods and compositions for the prevention and treatment of herpes virus infections. The invention provides antigenic peptides, and pharmaceutical compositions comprising complexes of antigenic peptides and adjuvants that can activate an immune response against herpes viruses. The invention also provides methods of making the antigenic peptides and complexes of antigenic peptides and adjuvants. Methods of use of the pharmaceutical compositions are also provided.


Patent
Agenus | Date: 2014-09-11

Provided are methods and compositions for the selection of targeting moieties capable of interacting with target moieties that are displayed on a target entity, as well as methods and compositions for the selection of entities capable of inducing phenotypic changes in target entities.


The present invention relates to methods for preparing and using multichaperone-antigen complexes. The present invention uses HOP affinity molecules in affinity methods to isolate multichaperone (multi-HSP)-antigen complexes. Such complexes have use in therapy.

Loading Agenus collaborators
Loading Agenus collaborators